PDPN and cancer: However, in the study conducted by Kato and Kaneko, the authors succeeded in developing a cancer-specific antibody, which is known as the cancer-specific monoclonal antibody (CasMab), thereby adding a sense of feasibility to the actual use of CAR T cell therapies that can specifically target PDPN [79].